Actionable news
0
All posts from Actionable news
Actionable news in BSX: BOSTON SCIENTIFIC Corp,

Argus Upgrades Boston Scientific, Sees Market Share Gains And Strong Growth Ahead

Boston Scientific Corporation NYSE:BSX - Argus Upgrades Boston Scientific, Sees Market Share Gains And Strong Growth Ahead

Boston Scientific Corporation BSX 0.76% shares are trading marginally above its peer multiple, which Argus’ David Toung believes still makes the stock attractive, given the company’s robust growth prospects.

Toung upgraded the rating on Boston Scientific from Hold to Buy with a price target of $33.

Strong Sales

The company reported strong Q2:16 sales, with more than 10 percent growth across five product segments.

The analyst pointed out that Boston Scientific had “recently launched a new MRI-compatible pacemaker, which is helping it to gain share in the pacing market. We think these gains are sustainable.”

Related Link: 13F From Paulson & Co. Shows Increased Stakes In Boston Scientific, Rite Aid, Office Depot, Facebook

Guidance And Estimates Raised

The company raised its 2016 guidance, increasing the sales guidance from $8.075–$8.225 billion to $8.270–$8.370 billion and the adjusted EPS guidance from $1.06–$1.10 to $1.07–$1.11.

Following the revised guidance, the EPS estimates for 2016 and 2017 have been raised from $1.08 to $1.11 and from $1.20 to $1.27, respectively.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

DateFirmActionFromTo
Sep 2016Argus ResearchUpgradesHoldBuy
Aug 2016CitigroupMaintainsBuy
Jul 2016JP MorganMaintainsOverweight

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.